ExonHit Partners with French Institute on Breast Cancer MDx

ExonHit licensed from Institut Gustave Roussy exclusive, worldwide rights to a tissue-based breast cancer signature that will developed into an assay.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register quickly here for free access.